Table 1.
Radiation inhibitory doses 50 (ID50) and inhibitory concentrations 50 (IC50) for cytotoxic drugs used to treat melanoma in clinic.
|
Cell
culture |
BRAF | NRAS | PTEN | irradiation | TMZ | Carbo | Paclitax | vemurafenib |
|---|---|---|---|---|---|---|---|---|
| Mutation | mutation | expression | ID50 (Gy) | IC50 (μM) |
IC50 (μM) |
IC50 (nM) |
IC50 (nM) | |
| YUCOT | V600E | WT | + | 5.4 | NR* | 26.7 | 4.3 | 94.0 |
| YUGANK | WT | Q61K | + | 5.0 | NR | 57.6 | 4.3 | NT** |
| YUGASP | WT | Q61L | + | 3.2 | 100 | 12.7 | 4.1 | NT |
| YUHOIN | WT | WT | + | 2.2 | NR | 33.1 | 4.0 | NT |
| YUKIM | WT | Q61R/WT | + | 3.6 | NR | 3.1 | 1.0 | NT |
| YUKOLI | V600E/WT | WT | + | 4.2 | NR | 14.4 | 2.9 | 138.0 |
| YUMAC | V600K | WT | + | 4.3 | 70 | 4.6 | 2.4 | 18.0 |
| YUMUL | WT | WT | − | 5.8 | NR | 11.3 | 2.5 | NT |
| YUMUT | V600E/WT | WT | − | 8.0 | NR | 46.1 | 1.3 | 160.0 |
| YURIF | V600K | WT | + | 4.8 | NR | 5.0 | 3.8 | 132.0 |
| YUROL | WT | WT | − | NR>8 | NR | 27.9 | 61.7 | NT |
| YUSAC | V600E | WT | + | 2.7 | NR | 7.0 | 4.9 | 22.0 |
| YUSIT1 | V600K/WT | WT | + | 3.7 | 15 | 6.0 | 4.1 | 21.0 |
| YUTICA | WT | Q61R/WT | + | 7.0 | NR | 10.3 | 4.2 | NT |
NR-Not reached, NT-Not tested, temozolomide is denoted by TMZ, carboplatin by Carbo, paclitaxel by Paclitax,